Drug Profile
Research programme: xenotransplantation - Infigen/Novartis
Latest Information Update: 24 Apr 2003
Price :
$50
*
At a glance
- Originator Infigen; Novartis
- Class
- Mechanism of Action Tissue replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Xenotransplant rejection
Most Recent Events
- 20 Mar 2001 Preclinical development for Xenotransplant rejection in USA (Unknown route)